Target RNA-triggered CRISPR-Cas12a2 preferentially cleaves collateral DNA over RNA
Nucleic Acids Research · 2026
DOI: 10.1093/nar/gkag578 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nucleic Acids Research, 2026. Verfasst von Sobita Kunwar und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry and Biochemistry, Utah State University, Logan, UT 84322, United States. Hauptthemen laut MEDLINE: CRISPR-Associated Proteins, DNA Cleavage, CRISPR-Cas Systems, RNA. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIH HHS, NIGMS NIH HHS, European Research Council Proof-of-Concept award.
Abstract (Originalsprache)
CRISPR-Cas systems often rely on collateral cleavage of nucleic-acid substrates to combat recognized mobile genetic elements. Of the CRISPR-associated (Cas) RNA-guided effector nucleases, Cas12a2 stands out as the only known example exhibiting rapid collateral cleavage of three distinct substrates: single-stranded (ss)RNA, ssDNA, and double-stranded (ds)DNA, after activating upon binding cognate RNA. However, little is known about the underlying mechanisms of collateral cleavage. Here, we show, using enzyme kinetics and inhibition assays, that Cas12a2 preferentially cleaves collateral DNA over RNA substrates, even when RNA substrates are more abundant. Additionally, using enzyme mutants, enzyme kinetics, and plasmid cleavage assays, we determine that the dsDNA cleavage mechanism relies on the ‘aromatic clamp’ residues that stabilize unwound and distorted dsDNA in the RuvC nuclease active site. Leveraging the cleavage preference for collateral DNA, we demonstrate that RNA-activated Cas12a2 can readily cleave a ssDNA probe in the presence of high concentrations of non-target RNA, while an RNA-targeting Cas13a cannot. This work provides foundational kinetic and biochemical insights into the collateral cleavage mechanism and substrate preferences of Cas12a2, with immediate implications for understanding Cas12a2-based immunity and developing Cas12a2-based technologies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Chemistry and Biochemistry, Utah State University, Logan, UT 84322, United States.
- Helmholtz Institute for RNA-based Infection Research (HIRI), Helmholtz Centre for Infection Research (HZI), Würzburg 97080, Germany.
- Center for Integrated Biosystems, Utah State University, Logan, UT 84322, United States.
- Medical Faculty, University of Würzburg, Würzburg 97080, Germany.
ORCID-Profile: Chase L Beisel, Ryan N Jackson
Förderung
- NIH HHS
- NIGMS NIH HHS
- European Research Council Proof-of-Concept award
- Helmholtz Center for Infection Research (HZI) Singh-Chhatwal-Postdoctoral Fellowship
- National Institutes of Health
- National Institute of General Medical Sciences
Zitieren
APA
Kunwar, S., Hallmark, T., Manna, S., Keiser, D., Naegle, B., Thomas, A., Beisel, C. L., & Jackson, R. N. (2026). Target RNA-triggered CRISPR-Cas12a2 preferentially cleaves collateral DNA over RNA. Nucleic Acids Research. https://doi.org/10.1093/nar/gkag578
Vancouver
Kunwar S, Hallmark T, Manna S, Keiser D, Naegle B, Thomas A, et al. Target RNA-triggered CRISPR-Cas12a2 preferentially cleaves collateral DNA over RNA. Nucleic Acids Research. 2026. doi:10.1093/nar/gkag578
BibTeX
@article{Kunwar2026,
author = {Kunwar, Sobita and Hallmark, Thomson and Manna, Sudeshna and Keiser, Dylan and Naegle, Bronson and Thomas, Aaron and Beisel, Chase L and Jackson, Ryan N},
title = {Target RNA-triggered CRISPR-Cas12a2 preferentially cleaves collateral DNA over RNA},
journal = {Nucleic Acids Research},
year = {2026},
doi = {10.1093/nar/gkag578}
}
EUVIMED